Vaxil Bio Ltd.
VXL.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 155.10K | 134.50K | 74.10K | 58.40K | 84.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 152.10K | 143.50K | 97.80K | 80.60K | 139.30K |
| Operating Income | -152.10K | -143.50K | -97.80K | -80.60K | -139.30K |
| Income Before Tax | -136.20K | -130.40K | -95.60K | -80.60K | -139.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.14 | -0.13 | -0.10 | -0.08 | -0.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -136.20K | -130.40K | -95.60K | -80.60K | -139.30K |
| EBIT | -152.10K | -143.50K | -97.80K | -80.60K | -139.30K |
| EBITDA | -- | -- | 23.20K | -1.00K | -95.20K |
| EPS Basic | -0.05 | -0.05 | -0.03 | -0.03 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 |
| EPS Diluted | -0.05 | -0.05 | -0.03 | -0.03 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.02 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 10.96M | 10.96M | 10.96M | 10.96M | 10.96M |
| Average Diluted Shares Outstanding | 10.96M | 10.96M | 10.96M | 10.96M | 10.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |